ADAMTS13-containing compositions having thrombolytic activity
This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
1. A method of treating or preventing deep vein thrombosis in a patient, the method comprising administering a pharmaceutical composition having thrombolytic activity and anti-thrombotic activity intravenously to the patient, wherein the pharmaceutical composition comprises a pharmaceutically effective amount of ADAMTS13 as an active ingredient.
2. The method of claim 1 , wherein ADAMTS13 is recombinant human ADAMTS13.
3. The method of claim 1 , further comprising administering one or more additional active ingredients.
4. The method of claim 3 , wherein the additional active ingredient is selected from the group consisting of an anti-thrombotic agent, an agent that stimulates ADAMTS13 production or secretion, an agent that inhibits ADAMTS13 degradation, an agent that enhances ADAMTS13 activity, and an agent that inhibits ADAMTS13 clearance from circulation.
5. The method of claim 4 , wherein the anti-thrombotic agent is selected from the group consisting of anti-platelets, t-PA, aspirin and heparin.
6. The method of claim 1 , wherein the pharmaceutically effective amount of ADAMTS13 or a biologically active derivative of ADAMTS13 ranges is from 0.1 to 20 mg/kg weight.
7. The method of claim 1 , wherein the patient is a human patient.
8. A method of treating or preventing deep vein thrombosis in a patient, the method comprising administering a pharmaceutical composition having thrombolytic activity and anti-thrombotic activity intravenously to the patient, wherein the pharmaceutical composition comprises a pharmaceutically effective amount of a chimeric molecule comprising ADAMTS13 and Ig.
9. The method of claim 8 , wherein ADAMTS13 is recombinant human ADAMTS13.
10. The method of claim 8 , further comprising administering one or more additional active ingredients.
11. The method of claim 10 , wherein the additional active ingredient is selected from the group consisting of an anti-thrombotic agent, an agent that stimulates ADAMTS13 production or secretion, an agent that inhibits ADAMTS13 degradation, an agent that enhances ADAMTS13 activity, and an agent that inhibits ADAMTS13 clearance from circulation.
12. The method of claim 11 , wherein the anti-thrombotic agent is selected from the group consisting of anti-platelets, t-PA, aspirin and heparin.
13. The method of claim 8 , wherein the pharmaceutically effective amount of the chimeric molecule is from 0.1 to 20 mg/kg weight.
14. The method of claim 8 , wherein the patient is a human patient.